Rallybio outlines expected milestones for 2022

Rallybio has provided an update on recent accomplishments and announced expected upcoming milestones.

“Our mission is to build Rallybio into a leading biotechnology company, with a broad and sustainable pipeline of product candidates that can transform the lives of people with severe and rare disorders and shatter expectations of what’s possible,” said Martin Mackay, Ph.D., Chief Executive Officer of Rallybio … more

The company reported that the first subjects have been dosed in its study of RLYB212, a novel human monoclonal antibody drug candidate designed to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT) … more